


Neonatal hypoglycaemia

Jane E Harding ¹, Jane M Alsweiler,^{2,3} Taygen E Edwards,¹ Chris JD McKinlay^{2,4}



For numbered affiliations see end of article.

Correspondence to: Professor Jane E Harding, Liggins Institute, University of Auckland, Auckland 1142, New Zealand; j.harding@auckland.ac.nz

Cite this as: *BMJMED* 2024;3:e000544. doi:10.1136/bmjmed-2023-000544

Received: 21 August 2023

Accepted: 4 March 2024

ABSTRACT

Low blood concentrations of glucose (hypoglycaemia) soon after birth are common because of the delayed metabolic transition from maternal to endogenous neonatal sources of glucose. Because glucose is the main energy source for the brain, severe hypoglycaemia can cause neuroglycopenia (inadequate supply of glucose to the brain) and, if severe, permanent brain injury. Routine screening of infants at risk and treatment when hypoglycaemia is detected are therefore widely recommended. Robust evidence to support most aspects of management is lacking, however, including the appropriate threshold for diagnosis and optimal monitoring. Treatment is usually initially more feeding, with buccal dextrose gel, followed by intravenous dextrose. In infants at risk, developmental outcomes after mild hypoglycaemia seem to be worse than in those who do not develop hypoglycaemia, but the reasons for these observations are uncertain. Here, the current understanding of the pathophysiology of neonatal hypoglycaemia and recent evidence regarding its diagnosis, management, and outcomes are reviewed. Recommendations are made for further research priorities.

Introduction

Neonatal hypoglycaemia (low blood concentrations of glucose) is the most common metabolic abnormality of the newborn, with glucose concentrations <2.6 mmol/L found in about 40% of neonates.¹ Neonatal hypoglycaemia occurs mainly in the first hours and days after birth as the neonate makes the transition from a continuous intravenous glucose supply across the umbilical circulation to the intermittent feed and fast cycle of milk feeding. Severe hypoglycaemia can cause brain injury and can be life threatening.^{2,3} The consequences of mild hypoglycaemia are less certain, however, and the definitions of both vary widely.⁴ Also, mild hypoglycaemia is commonly asymptomatic, so screening by intermittent blood testing is usually recommended for infants at increased risk, with treatment when low levels of glucose are detected.^{5,6} Up to 30% of infants belong to commonly accepted risk categories,⁵ making the risk of neonatal hypoglycaemia arguably the most common reason for medical intervention in neonates after initial resuscitation.

Although the pathophysiology of this common problem is beginning to be understood, high certainty evidence on which to base clinical decisions is scarce. This lack of evidence contributes

to the wide variation in practice of screening protocols, thresholds for diagnosis, and appropriate treatment. Over the past ten years, several randomised trials and large cohort studies have provided new insights into these and other aspects of neonatal hypoglycaemia. Some promising new approaches that could enhance the management of neonatal hypoglycaemia in the future have also been reported. Here, we review the more recent evidence on the management of neonatal hypoglycaemia, with a focus on transitional neonatal hypoglycaemia, areas of continuing uncertainty, and potential future developments.

Sources and selection criteria

Between March and April 2023, we searched PubMed and Medline for articles on neonatal hypoglycaemia published between 1 January 2010 and 31 March 2023. We cross referenced the search terms “hypoglycaemia,” “hypoglycemia,” “glucose,” “glycaemia,” “glycemia,” “dextrose gel,” “glucagon,” and “diazoxide,” with variations of neonate, including “neonate,” “postnatal,” “baby,” and “infant.” We selected more recent publications but did not exclude commonly referenced and highly regarded older publications. We searched only for articles published in English, or those translated into English. We also searched reference lists of articles identified by this strategy and selected those we judged to be relevant. We prioritised peer reviewed systematic reviews and large clinical trials, but also included observational studies, retrospective studies, guidelines, and review articles.

Definitions

Hypoglycaemia, defined as low blood concentrations of glucose, is not in itself a diagnosis, but rather a screening test for an inadequate brain supply of glucose (neuroglycopenia) and, rarely, a sign of an underlying endocrine or metabolic disorder. Neonatal hypoglycaemia can be classified by the type of episodes, cause, and time course, although overlap can occur with respect to the underlying pathophysiology, and distinction between the different groups is often only possible in retrospect.⁷ An episode refers to one or more sequential blood glucose concentrations below a defined operational threshold. Episodes are further classified by the lowest concentration of glucose, with a severe episode commonly defined as <2.0 mmol/L and a mild episode ≥2.0 mmol/L, and by their frequency, with recurrent hypoglycaemia commonly defined as three or more episodes (table 1).

Table 1 | Commonly used definitions in hypoglycaemia. Definitions of thresholds such as mild and severe vary widely

Term	Definition
Hypoglycaemic episode	One or more measurements of glucose concentration below a defined operational threshold
Severe episode	Lowest glucose concentration <2.0 mmol/L
Mild episode	Lowest glucose concentration <2.6 mmol/L
Recurrent hypoglycaemia	≥3 episodes
Transitional hypoglycaemia	Low concentrations of glucose caused by delayed metabolic transition after birth
Prolonged transitional hypoglycaemia	Transitional hypoglycaemia persisting beyond 72 hours after birth
Operational threshold	Glucose concentration when intervention is considered appropriate to minimise risk of brain injury
Neuroglycopenia	Inadequate brain metabolic substrates for glycolysis

Classification of neonatal hypoglycaemia

In term and near term newborn infants who do not have any underlying disorders and are otherwise healthy, hypoglycaemia is classified as transitional, representing a delay in the normal physiological adaptation from fetal life. About 40% of infants with transitional hypoglycaemia have severe or recurrent episodes.⁸ Secondary causes of hypoglycaemia include acute illness, such as sepsis and hypoxic ischaemic encephalopathy, and moderate or very preterm birth. The primary causes include congenital malformations that affect endocrine function, and genetic disorders of glucose or intermediary metabolism. Transitional neonatal hypoglycaemia often resolves within 48 hours and is considered brief, but occasionally transitional neonatal hypoglycaemia persists beyond 72 hours and is termed prolonged transitional hypoglycaemia. Prolonged transitional hypoglycaemia usually resolves within weeks but can continue for a few months and is a diagnosis of exclusion, made in retrospect.⁹

Primary causes should be considered, particularly in the presence of acidosis or alkalosis; bradycardia or arrhythmia; conjugated hyperbilirubinaemia; micropenis, microcephaly, or cleft palate (potential markers of hypothalamic or pituitary defects); a family history of infant hypoglycaemia; persistently absent ketones; very high insulin concentrations; or a normal insulin:glucose ratio during hypoglycaemia (≤ 1.0 mU/mmol). The rate of prolonged transitional hypoglycaemia is reported to be about six per 10000 births.¹⁰ The primary inherited causes are similarly rare, usually requiring ongoing treatment and monitoring throughout infancy, and are sometimes referred to as persistent hypoglycaemia of infancy.

Physiology of the metabolic transition

The physiological changes that support transition from fetal to extrauterine life are profound, unique, and unequalled elsewhere in the life course. Survival after birth depends on establishing pulmonary blood flow, lung aeration, and regular breathing.¹¹ After this initial cardiopulmonary transition, ongoing survival depends on activation of the liver to provide energy substrates, previously supplied by the placenta, to support oxidative metabolism of tissues. Adequate hepatic energy production is crucial, especially until enteral feeds are well established. In the early newborn period, glucose is the main energy substrate, followed by lactate and ketone bodies,¹² although ketogenesis in the first 6-12 hours after birth is minimal, even in healthy neonates.^{13 14}

With normal uteroplacental function, the fetus receives a continuous supply of glucose from the mother, and fetal glucose synthesis is negligible. This process allows the fetus to maintain an anabolic state to achieve growth, and a high fetal insulin to glucagon molar ratio (up to 10-15) promotes glycogenesis and lipogenesis in preparation for postnatal life.^{15 16} With the cutting of the cord, infants must start hepatic glucose output from glycogenolysis and gluconeogenesis to prevent hypoglycaemia and neuroglycopenia. In late gestation, mean fetal glucose concentrations are about 3.5 mmol/L^{17 18} and increase to about 4.6 mmol/L during normal labour. Slightly higher concentrations are reported after instrumental birth (about 5.8 mmol/L) and lower concentrations after elective caesarean section (about 3.9 mmol/L).¹⁹⁻²¹ After birth, neonatal blood glucose concentrations fall to a mean of about 2.9 mmol/L by age 30 minutes,^{22 23} increasing to about 3.1 mmol/L by age 60-90 minutes.^{24 25} Thereafter, mean blood glucose concentrations before feeding in healthy, breastfed, term infants are 3.3 mmol/L in the first 48 hours after birth, gradually increasing to 4.5 mmol/L by 96 hours.^{1 14 26} The 10th centile for blood glucose concentrations in the period from two to 48 hours after birth in healthy, term, breastfed infants is 2.6 mmol/L (figure 1).^{1 14}

Before birth, the rise in fetal cortisol production in late pregnancy induces expression of several hepatic enzymes that represent rate limiting steps in glucose production, including phospho-phenolpyruvate carboxykinase (gluconeogenesis) and glucose-6-phosphatase (glycogenolysis and gluconeogenesis).^{27 28} In rodents and sheep, the main trigger for the onset of hepatic glucose production after birth is a rapid fall in the insulin to glucagon ratio, mainly because of a surge in glucagon secretion from pancreatic α cells but also from reduced release




Figure 1 | Centiles of plasma and interstitial concentrations of glucose over the first five days in healthy term newborns. The 10th centile, in the period from two to 48 hours after birth, is about 2.6 mmol/L. Adapted and reproduced with permission from Harris et al¹

fetal catecholamines, thyroxine, and cortisol are likely to play a part (figure 2).²⁹ An important functional change in the β cell that supports postnatal glucose homeostasis is an increasing ability to suppress secretion of insulin at low concentrations of blood glucose, which requires an increase in the low fetal glucose set point for secretion of insulin.^{30 31} Recent evidence in rodents suggests that the shift of β cells from constitutive to mature glucose regulated insulin secretion after birth might be mediated by activation of dynamic signalling from the mechanistic target of rapamycin complex 1 (mTOR1).³²

With the fall in the insulin to glucagon ratio, lipolysis increases and glycerol is produced, providing a key substrate for gluconeogenesis as glycogen is depleted.^{33 34} Thyroxine and cortisol also enhance lipolysis in neonates.^{35 36} As hepatic fatty acid oxidation increases on the first day, more cofactors and ATP are generated within the liver to support gluconeogenesis, whereas fatty oxidation in peripheral tissues inhibits glucose oxidation and stimulates the production of more gluconeogenic precursors, including lactate, pyruvate, and alanine.³⁷

of insulin from β cells.^{16 29} Similar physiology has been shown in the human neonate.³⁰ The mechanisms that underlie the postnatal adaptations in the endocrine pancreas are not fully understood, although the peripartum surges in

Pathophysiology of neonatal hypoglycaemia

Although some infants with transitional hypoglycaemia can have high concentrations of insulin, the most common physiological feature of these infants is inadequate suppression of insulin at low concentrations of blood glucose, indicating a delay




Figure 2 | Postnatal adaptations to support glucose homeostasis. Catecholamines, cortisol, and thyroxine stimulate lipolysis in adipose tissue and glucagon secretion from pancreatic α cells. Pancreatic β cells transition from constitutive to mature glucose regulated insulin secretion, which involves a rise in the glucose set point for release of insulin and greater suppression of insulin as blood concentrations of glucose fall. The decreasing insulin to glucagon ratio after birth is a key stimulus for hepatic glucose output, triggering both glycogenolysis (release of glucose from stored glycogen) and synthesis of glucose (gluconeogenesis) from glycerol (product of lipolysis), lactate, and other precursors, including gluconeogenic amino acids (eg, alanine). Increasing hepatic fatty acid oxidation on the first day not only provides substrate for ketogenesis but also generates more cofactors and ATP in the liver to support gluconeogenesis. Increasing fatty oxidation in peripheral tissues produces more gluconeogenic precursors

in postnatal adaptation of the β cell from the fetal state.¹⁰ Thus insulin concentrations in infants with transitional hypoglycaemia are typically not high but are inappropriately raised for the preprandial state.¹⁰

The physiological mechanisms underlying impairments in metabolic transition are not fully understood. In sheep, fetal growth restriction results in chronically raised concentrations of catecholamines that suppress fetal secretion of insulin; loss of this negative feedback after birth seems to contribute to persistence of a more fetal-like pattern of insulin secretion.³⁸ Studies in rodents suggest that the blood glucose threshold for insulin secretion in the immature β cell is inversely proportional to the cell surface density of ATP sensitive potassium channels (K_{ATP}).³⁹ K_{ATP} contribute to cell membrane polarisation by potassium efflux and are responsible for depolarisation as glucose generated ATP increases (channel closure reduces potassium ion efflux), triggering release of insulin vesicles. Hypoxia seems to reduce K_{ATP} density, resulting in decreased membrane polarity and a lower threshold for release of insulin, although the effect of clinical risk factors on K_{ATP} trafficking has yet to be determined. Similarly, relatively little is known of the effect of pregnancy complications on α cell development,⁴⁰ but maternal glucose intolerance could result in β cell hyperplasia or hypertrophy, or both,⁴¹ and decrease fetal α cell proliferation in late pregnancy.⁴² The peptide hormone urocortin 3 could have a role in fine tuning both β cell and α cell maturation.⁴³

The main metabolic consequence of a failure to adequately suppress secretion of insulin after birth as blood concentrations of glucose fall is reduced hepatic glucose output and impaired ketogenesis.¹⁰³⁰ This mechanism contributes not only to the risk of neuroglycopenia but also to the lower than average blood concentrations of glucose seen in infants with transitional hypoglycaemia. Insulin inhibits lipolysis in adults, but release of glycerol and fatty acids might be relatively preserved in newborn infants,^{44 45} possibly a result of a greater counter-regulatory effect of cortisol and catecholamines in adipose tissue than in the liver.⁴⁶ Thus even infants with severe hypoglycaemia usually have detectable free fatty acids in plasma, although ketones are frequently absent.¹⁰

Neuropathology of hypoglycaemic injury

The neonatal brain is dependent on a continuous supply of glucose to generate energy as ATP, because developing neurons have reduced capacity to use alternative substrates and limited high energy phosphate reserves.⁴⁷ Also, rodent studies have shown that maximal expression of glucose transporter proteins (GLUT1 and GLUT3) at the blood-brain barrier that enable glucose uptake into the brain by facilitated diffusion might take several days to weeks.⁴⁷

Neuroglycopenia describes a state of metabolic imbalance caused by low glycolysis that triggers a series of cellular events that impair function, cause injury and, if not reversed, ultimately lead to cell necrosis. Rodent studies have indicated that at least three mechanisms could contribute to cytotoxicity in neuroglycopenia (figure 3).^{48 49} Firstly, neuronal depletion of pyruvate, which is normally oxidised by the citric acid cycle, results in intracellular deficiency of oxaloacetate. This deficiency in turn leads to excess generation of the excitatory neurotransmitter glutamate, which is released into the extracellular space around neurons and causes sustained influx of calcium by means of the glutamate receptor, thereby initiating excitotoxicity. High intracellular concentrations of calcium activate several enzymes, including phospholipases, endonucleases, and proteases, which damage cell structures.

Secondly, an increase in free intracellular zinc, caused by excitatory release and influx of calcium and damage to zinc containing organelles, activates nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, leading to superoxide production in mitochondria. Thirdly, hyperactivation of poly-ADP-ribose-polymerase 1 (PARP-1) by calcium and superoxide contributes to mitochondrial damage and cytosolic depletion of nicotinamide adenine dinucleotide (NAD⁺), which further inhibits glycolysis. Neuroglycopenia mainly affects neurons, although glial cells could be susceptible to injury when hypoglycaemia is combined with hypoxia.⁵⁰ Hypoglycaemia induced apoptosis has also been reported in immature oligodendrocytes.⁵¹

A key challenge in the management of neonatal hypoglycaemia is the current lack of clinical devices that can detect and monitor neuroglycopenia. Furthermore, as cell injury progresses, giving exogenous glucose could worsen cell injury. When NAD⁺ is depleted during hypoglycaemia, reperfused glucose is shunted through the hexose monophosphate pathway, generating NADPH and more superoxide.⁵² Of concern is that in rodent studies, the rate of superoxide production is proportional to blood glucose concentrations after insulin induced hypoglycaemia.

This phenomenon of glucose reperfusion injury could explain why apparently brief, mild episodes of neonatal hypoglycaemia, if untreated, have been associated with reduced educational achievement,⁵³ although in infants who have received treatment, identifying a safe lower limit and length of neonatal hypoglycaemia has proved challenging.⁵⁴ Glucose reperfusion injury also raises the question of the extent to which the long term cognitive deficits after severe or recurrent hypoglycaemia⁸ are caused by hypoglycaemia itself or the interventions received. For example, in a large prospective cohort of 477 infants born at risk of transitional hypoglycaemia, those with neurosensory impairment at age two and 4.5 years had higher and more rapid increases




Figure 3 | Schematic model of cellular mechanisms in neuroglycopenia. Suppression of glycolysis from reduced neuronal uptake of glucose depletes intracellular pyruvate, which in turn reduces production of oxaloacetate by the citric acid cycle and pyruvate carboxylase. Replenishment of oxaloacetate by aspartate transaminase (AST) generates excess glutamate, an excitatory neurotransmitter. Increasing amounts of glutamate in the extracellular fluid around neurons causes sustained neuronal excitation by glutamate receptors. High calcium (Ca^{2+}) influx initiates excitotoxicity, including hyperactivation of poly-ADP-ribose-polymerase 1 (PARP-1), contributing to mitochondrial damage and cytosolic depletion of nicotinamide adenine dinucleotide (NAD⁺). An increase in free zinc (Zn^{2+}) stimulates excess reactive oxygen species by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. NADH=reduced nicotinamide adenine dinucleotide; acetyl-CoA=acetyl coenzyme A

in blood concentrations of glucose after hypoglycaemia, especially after treatment with exogenous dextrose.^{55 56}

In several animal studies, treating hypoglycaemia with substrates that can be metabolised without NAD⁺, such as lactate, ketones, and pyruvate, reversed cell injury,^{57–59} suggesting that these substrates could have a neuroprotective role in neonatal hypoglycaemia. The extent to which this effect occurs in humans has yet to be studied.

Challenges in screening for hypoglycaemia

Neonatal hypoglycaemia is commonly asymptomatic, unless severe, and clinical assessment has poor sensitivity and specificity for detecting infants with low blood concentrations of glucose.⁶ Therefore, most guidelines recommend that infants with known risk factors (eg, maternal diabetes, small or large for gestation, or born preterm) are screened by regular testing for blood glucose concentrations,⁵ but there are several difficulties with this approach.

Firstly, screening for neonatal hypoglycaemia arguably does not meet the criteria for a valid screening programme (table 2).⁶⁰ Screening programmes should look for a condition where the natural history of the disease is understood, a reliable diagnostic test for the condition of interest in

those with a positive screen (in this case, neuroglycopenia) is available, a treatment that has been shown to improve outcomes for those at a presymptomatic stage compared with usual care is available, and the overall benefits of screening should outweigh the harm.^{61–63} The natural history of transitional neonatal hypoglycaemia and its effects on long term neurodevelopmental outcomes, however, are not well understood.^{4 64} No direct evidence exists from randomised trials that treatment of hypoglycaemia improves long term neurodevelopmental outcomes⁶⁵ or that the benefits of screening outweigh harm. For some infants, screening might cause more harm than good. As well as the pain caused by heelprick blood tests,⁶⁶ in retrospective observational studies of 10 533 and 10 965 infants, respectively, those who were screened for neonatal hypoglycaemia were more likely to be given formula and less likely to be exclusively breastfed, even if their blood glucose concentrations were normal.^{67 68} Infants with risk factors for neonatal hypoglycaemia, however, such as those whose mothers had diabetes and those born by caesarean section, had a higher risk of not being breastfed, independent of hypoglycaemia,⁶⁹ so determining if this association is causal is difficult.

Secondly, operational thresholds to define neonatal hypoglycaemia in asymptomatic infants

Table 2 | Assessment of screening for neonatal hypoglycaemia against the criteria for an effective screening programme

	Screening principle ⁵⁰	Comments	Meets criteria
Condition	The condition should be an important health problem	Severe neonatal hypoglycaemia is rare but probably causes brain injury. Transitional hypoglycaemia is common and associated with developmental delay	Yes
	The natural history of the condition, including development from latent to declared disease, should be adequately understood	The natural history of the condition (ie, the risk of brain injury from transitional neonatal hypoglycaemia) is poorly understood	No
	A recognisable latent or early symptomatic phase should be present	Hypoglycaemia is commonly asymptomatic. Even one incidence of a low blood glucose concentration, however, has been associated with poor academic outcomes	Maybe
Test	A suitable test or examination should be available	Testing for blood concentrations of glucose is simple, although painful. A reliable test for neuroglycopenia to determine which infants with a positive screening test would benefit from intervention is not yet available	No
	The test should be acceptable to the population	No data on acceptability of the test to parents or infants (as adults)	No
Intervention	An accepted treatment for patients with recognised disease should be available	Treatment options include oral dextrose gel, formula, intravenous dextrose, diazoxide, and glucagon. No direct evidence exists that any of these interventions improve neurodevelopment	No
	An agreed policy on who to treat as patients should exist	Target population varies from country to country, but all guidelines recommend screening infants born preterm, small for gestational age, and to mothers with diabetes. Screening in infants born large for gestational age is contentious	Yes
Screening programme	The cost of case finding (including diagnosis and treatment of patients with a diagnosis) should be economically balanced in relation to possible expenditure on medical care as a whole	No data are available on the cost effectiveness of screening for neonatal hypoglycaemia	No
Implementation criteria	Case finding should be a continuing process and not a once and for all project	—	Yes
	Facilities for diagnosis and treatment should be available	Inaccurate non-enzymatic analysers are frequently used to diagnose neonatal hypoglycaemia	Maybe

vary because of the uncertain relation between blood concentrations of glucose and neuroglycopenia, with different guidelines ranging from blood glucose thresholds of <2.0 mol/L⁷⁰ to <2.8 mmol/L⁹ (table 3). In a large, randomised controlled trial, 689 infants with mild hypoglycaemia were randomised to a lower threshold (treatment given at a glucose concentration of <2.0 mmol/L) or a traditional threshold (treatment given at a glucose concentration of <2.6 mmol/L). The lower threshold was non-inferior to the traditional threshold for neurodevelopmental outcome at age 18 months.⁷¹ Assessing neurodevelopment is more accurate when children are older, however, and age 18 months might be too young to detect important, higher cognitive functions that emerge at later stages of development, especially executive function and advanced visual-motor integration. Furthermore, screening is often

done with inaccurate cotside tests,⁷² although more accurate and likely cost saving methods are now available.⁷³

Thirdly, although about 50% of 514 infants with traditional risk factors (infant of a mother with diabetes, large or small birth weight, and born preterm) developed hypoglycaemia, in a recent prospective observational study, the frequency of low blood concentrations of glucose was similar in 67 healthy term infants with no risk factors.¹⁷⁴ Also, in retrospective observational studies, either none of the risk factors used for screening were associated with hypoglycaemia⁷⁵ or only insulin treatment for maternal gestational diabetes was predictive.⁷⁶ Although the frequency of hypoglycaemia in infants with risk factors might not be greatly increased, these infants could be more sensitive to the effects of hypoglycaemia on neurodevelopment than infants

Table 3 | Examples of guidance for management of asymptomatic neonatal hypoglycaemia

Guideline (listed in date order); scope	Glucose concentration threshold for intervention (mmol/L)	Target glucose concentration during treatment (mmol/L)	First line treatment	Second line treatment	Third line treatment	Length of monitoring if glucose normal	Length of monitoring after last low glucose measurement	Further investigation and referral
WHO 1997 ¹²² ; newborns at risk	<2.6	>2.6	Feeding	Intravenous 10% dextrose 60 mL/kg/day	NS	NS	NS	NS
AAP 2011 ⁷⁸ ; late preterm and term infants at risk	<1.4 if <4 hours, <1.9 if 4-24 hours	>2.5 before feeds	More feeding	Intravenous 10% dextrose 80-100 mL/kg/day (5-8 mg/kg/min) or bolus 2 mL/kg 10% dextrose, or both	NS	12 hours for infant of mother with diabetes and large for gestational age, 24 hours for preterm and small for gestational age	NS	Glucose <2.5 mmol/L after 24 hours, intravenous dextrose 5-8 mg/kg/min
BAPM 2017 ¹⁰⁶ ; term newborns in first 48 hours	<1.0 or two values <2.0	>2.0 initially, >2.6 if receiving intravenous dextrose	Feeding support	Buccal 40% dextrose gel 0.5 mL/kg with feeding support	Intravenous 10% dextrose 60 mL/kg/day	Until two glucose samples >2.0 mmol/L taken before feeds	Until glucose >2.6 mmol/L for at least 24 hours	>8 mg/kg/min intravenous dextrose
Canada 2019 ¹⁰⁷ ; newborns at risk	<2.6 if <72 hours, <2.8 if ≥72 hours	>2.6 if <72 hours, >3.3 if ≥72 hours	More feeding	Buccal 40% dextrose gel 0.5 mL/kg with feed	Intravenous 10% dextrose 80 mL/kg/day (5.5 mg/kg/min), Bolus 2 mL/kg 10% dextrose	12 hours for infant of mother with diabetes and large for gestational age, 24 hours for small for gestational age and preterm	Until two samples in normal range taken before feeds	>10 mg/kg/min intravenous dextrose and aged >72 hours
Switzerland 2020 ¹²³ ; late preterm and term infants on maternity wards	<2.6	≥2.6	Buccal 40% dextrose gel 0.5 mL/kg with more feeds	NS	NS	Three measures >2.6 mmol/L taken before feeds	NS	Glucose <2.6 mmol/L after feeds with dextrose gel
ABM ¹⁰⁹ ; late preterm and term infants	<2.5	≥2.5	More feeding	Buccal 40% dextrose gel 0.5 mL/kg with feeding plan	Intravenous dextrose bolus 1-2 mL/kg 10% dextrose, infusion 5-8 mg/kg/min	Three measures >2.5 mmol/L taken before feeds, preterm and small for gestational age for 24 hours	Blood glucose >3.9 mmol/L over several fast feed cycles if hypoglycaemia persists for >4 days or requiring intravenous dextrose	>72 hours or requiring >10-12 mg/kg/min dextrose
Queensland ¹²⁴ ; babies at risk	<2.6 if <48 hours, <3.3 if ≥48 hours, <4.0 if known hypoglycaemic disorder	>2.6 if <48 hours, >3.3 if ≥48 hours, >4.0 if known hypoglycaemic disorder	If 1.5-2.5 mmol/L, buccal 40% dextrose gel 0.5 mL/kg with more feeds. If <1.5 mmol/L, gluca- gon 200 µg/kg	Intravenous 10% dextrose 1-2 mL/kg bolus and infusion 60 mL/kg/day (4.2 mg/kg/min)	Another intravenous dextrose bolus 1 mL/kg	24 hours	Until ≥2.6 mmol/L for 24 hours in first 48 hours or >3.3 mmol/L after 48 hours or ≥4.4 mmol/L after 6 hour fast if known hypoglycaemic disorder	Persistent or recurrent despite ≥8 mg/kg/min intravenous dextrose, clinical features, or family history

.AAP, American Academy of Paediatrics; ABM, Association of Breastfeeding Medicine; BAPM, British Association of Perinatal Medicine; NS, not specified; WHO, World Health Organization.

with no risk factors (see section on long term consequences below).⁷⁷

Fourthly, consensus is lacking on the appropriate length and frequency of testing for blood glucose in infants at risk of hypoglycaemia (table 3). Most guidelines recommend screening for 8-24 hours after birth,^{70 78} although most infants with risk factors who then require intravenous dextrose are identified from the first or second blood glucose test.⁷⁵ Further research is needed to determine how long and how often infants at risk of hypoglycaemia should be monitored with intermittent testing of blood glucose to detect infants with hypoglycaemia whose long term outcomes can be improved with treatment.

Newer approaches to monitoring

Measurement of glucose concentrations in plasma by laboratory chemical analyser or whole blood by gas analyser remains the gold standard for detection of hypoglycaemia. A renewed focus on developing better approaches to continuous monitoring of tissue glucose has been reported, however, potentially allowing blood sampling to be used for confirmatory testing rather than screening. Measurement of tissue glucose in neonates is challenging because of the low operating range required, and the potential for rapidly changing blood glucose concentrations, which can make calibration of tissue readings difficult.⁷⁹

In adults and children, a range of commercial amperometric filament sensor devices are available for continuous monitoring of glucose in subcutaneous tissue. The sensors measure electric current generated by the oxidation of glucose from the interstitial fluid when a voltage is applied. The sensors require a barrier membrane to limit access of glucose to the filament because of the limited oxygen availability,⁷⁹ resulting in a relatively long wet-in phase before a reading can be obtained, usually two hours, and optimal function might not be achieved for 4-6 hours. Build up of biofilm on the sensor membrane also makes the devices susceptible to drift. Although drift has not been formally quantified in neonates, it could be substantial relative to the lower glucose operating range. Common drug treatments, such as paracetamol, can also contribute to drift in some devices.

Another limitation of subcutaneous sensors is their dependence on diffusion of glucose from the vascular compartment to the interstitial fluid, and equilibration times could be up to 30 minutes when blood glucose concentration is falling.⁸⁰ Calibration during this physiological lag phase will increase negative bias in tissue glucose concentrations, potentially leading to unnecessary intervention.

Although the use of subcutaneous amperometric sensors in neonatal intensive care is increasing, none of the current systems has been designed for neonates. Drift, physiological lag, and the inherent

noise of the sensor result in poor point accuracy, with 95% limits of agreement of at least ± 1 mmol/L.^{81 82} These large errors relative to the target blood glucose concentrations in neonates makes clinical interpretation difficult. Trend alarms might be more useful for predicting when blood glucose concentrations are most likely to be out of range. Trend monitoring of current commercial devices is not well suited to neonates, however, requires additional clinical judgment, and performance has not been fully validated, although such studies are underway.⁸³ New generation adult and paediatric subcutaneous sensors are designed to be used without calibration, but whether the factory set algorithms will improve or worsen performance in neonates, given their different transitional physiology, is not clear.

For research, sensor error can be minimised by retrospective recalibration of the raw current through all measured blood glucose concentrations.⁸⁴ This approach also allows for estimation of glucose concentrations <2.2 mmol/L (40 mg/dL), the lower limit of real time display for most devices. One promising technology in development is the glucose spectrometer, which uses the distinct infrared absorption pattern of glucose to measure tissue glucose.⁸⁵ Miniaturisation of narrow wavelength light emitting diodes that can act as emitters and detectors has allowed development of low cost wearable devices in a form suitable for neonates. In contrast with subcutaneous sensors which measure glucose in interstitial fluid, glucose spectrometers measure glucose mainly in blood in the underlying tissue, thereby avoiding problems of drift and physiological lag. In a proof of concept study, 93% of spectrometer estimated blood glucose concentrations were within the Clark error grid clinically acceptable range (sections A and B of the grid).⁸⁵

Long term consequences

The rationale for screening and treatment for neonatal hypoglycaemia is the prevention of brain injury. Low quality evidence suggested that severe, prolonged hypoglycaemia can result in major damage and even death, although many infants had comorbid conditions, which might have affected the outcomes.^{2 3 86} In children with persistent hyperinsulinaemia, poor neurological outcomes were common, and were seen more often in those who had more severe hypoglycaemia or seizures, or when delays in detection and treatment occurred.³

A meta-analysis of older and lower quality studies (six studies, 1657 children) reported similar odds of combined neurodevelopmental impairment from age two and five years in children who did and did not have neonatal hypoglycaemia (definitions ranged from <1.1 mmol/L to 2.6 mmol/L; odds ratio 1.16, 95% confidence interval (CI) 0.86 to 1.57).⁴ The meta-analysis also reported that those who had neonatal hypoglycaemia were more likely to have

neurodevelopmental impairment when assessed at age 6-11 years (two studies, 54 children; odds ratio 3.62, 1.05 to 12.42).

More recent evidence suggests that even mild, brief, and asymptomatic neonatal hypoglycaemia could be associated with poorer outcomes, although the evidence is conflicting and causal relations are uncertain. A large secondary analysis of a randomised trial cohort of 1194 late preterm and term infants, born at risk of neonatal hypoglycaemia and screened and treated if hypoglycaemia was detected, nevertheless found that neonatal hypoglycaemia (<2.6 mmol/L) was associated with poorer neurodevelopment at age two years (adjusted risk ratio 1.28, 95% CI 1.01 to 1.60), and this risk was greater after more severe hypoglycaemia (<2.0 mmol/L; adjusted risk ratio 1.68, 1.20 to 2.36).⁷⁷ Similarly, a large population based cohort study of 101 060 infants reported that moderate neonatal hypoglycaemia (<2.2 mmol/L) was associated with an increased risk of any neurological and neurodevelopmental impairment at age 2-6 years (adjusted risk ratio 1.48, 1.17 to 1.88).⁸⁷

Evidence from randomised trials is limited and conflicting. Two trials of the use of prophylactic dextrose gel to reduce the incidence of hypoglycaemia in infants at risk both reported that infants randomised to receive the dextrose gel had a lower risk of neonatal hypoglycaemia (<2.6 mmol/L, relative risk 0.79, 95% CI 0.64 to 0.98, n=416 and 0.88, 0.80 to 0.98, n=2149).^{88 89} At age 2 years, both studies reported no difference between the groups in the main outcome of risk of neurosensory impairment.^{90 91} The first trial, however, reported a trend towards improved secondary outcomes related to language, motor, and executive function in the dextrose gel group who had less hypoglycaemia,⁹⁰ whereas the second trial reported worse language, motor, and cognitive function⁹¹ in the dextrose gel group.

These different findings might be in part because the characteristics of the infant, characteristics of hypoglycaemia (eg, length, severity, and recurrence), availability of alternative brain substrates, and even treatment all interact to determine developmental outcomes. For example, including infants with comorbid conditions, often hypoxia-ischaemia, might confound relations between neonatal hypoglycaemia and later outcomes.^{55 92} In contrast, the longer term consequences of neonatal hypoglycaemia are more easily detectable in cohorts of otherwise healthy infants with no acute neonatal illnesses.^{77 87} Infants who have neonatal hypoglycaemia at 12-24 hours after birth might also be more at risk of poorer neurodevelopment than those who have neonatal hypoglycaemia in the first 12 hours or after 24 hours because of low levels of neuroprotection from alternative sources of energy, such as lactate and ketone bodies.¹³ No clear evidence exists, however, that the

timing of neonatal hypoglycaemia affects longer term outcomes.⁸⁷

Recent data also raise the question of whether transitional hypoglycaemia, particularly if mild, is actually a marker of physiological instability associated with adverse development, rather than a cause, and distinguishing these possibilities is challenging. The Children with Hypoglycaemia and Their Later Development (CHYLD) prospective cohort study reported that in 477 moderate to late preterm and term infants born at risk of neonatal hypoglycaemia, those who had hypoglycaemia (<2.6 mmol/L) were more likely to have executive dysfunction (adjusted risk ratio 2.32, 95% CI 1.17 to 4.59) and poor visual-motor function (adjusted risk ratio 3.67, 1.15 to 11.69) at age 4.5 years,⁸ but these poorer outcomes did not persist at age 9-10 years (480 children; adjusted risk ratio 0.95, 0.78 to 1.15).⁵⁴ These at-risk children had similarly high rates of poor educational achievement, regardless of neonatal hypoglycaemia, suggesting that the main reason for being at risk, rather than the hypoglycaemia itself, might have contributed to their developmental trajectory. This interpretation could also explain why in the large randomised trial of dextrose gel prophylaxis, a treatment that reduced the risk of hypoglycaemia did not seem to reduce the risk of later adverse outcomes,⁹¹ despite hypoglycaemia being associated with poorer neurodevelopment in the same participant cohort.⁷⁷

Treatment

Feeding

Initial treatment of hypoglycaemia is usually more feeding, but evidence to support this approach as the only treatment is lacking. Breastfeeding is important for all infants, but in the first days after birth, when hypoglycaemia is most common, breast milk volumes are small^{93 94} and lactose and therefore calorie content is low.⁹⁵ This effect could explain why in healthy term infants, little or no increase in blood concentrations of glucose after breastfeeding is seen in the first 48 hours after birth.⁹⁶ In this prospective cohort study of 62 healthy term infants, the increase in blood glucose concentrations after feeding in the first five days was greater after prolonged breastfeeding (>30 min) and feeding from both breasts.

In another cohort study of 227 infants with hypoglycaemia in the first 48 hours, small increases in blood glucose concentrations (about 0.2 mmol/L) after formula feeding or dextrose gel (see section on dextrose gel below) were reported but not after expressed breast milk or breastfeeding.⁹³ Breastfeeding was associated with a reduced risk of recurrent hypoglycaemia, however, perhaps by non-milk mechanisms (ie, stimulation of secretion of gastrointestinal hormones, such as gastrin and cholecystokinin).⁹⁷ Another matched cohort study (33 infants in each group) also reported greater increases in blood glucose concentrations in infants

with hypoglycaemia given dextrose gel together with donor milk or formula (about 1 mmol/L) than in those given dextrose gel with breastfeeding (about 0.4 mmol/L).⁹⁸ Although expression of breast milk either before or after birth is often recommended to provide milk for babies at risk of or who develop neonatal hypoglycaemia, no evidence exists that this practice alters neonatal blood glucose concentrations or the risk of hypoglycaemia.^{99–100} A practical approach to feeding the infant with hypoglycaemia might therefore be to encourage breastfeeding, including for longer periods and from both breasts, rather than expressing breast milk, and consider adding dextrose gel, donor milk, or infant formula.

Dextrose gel

Dextrose gel is usually given to infants with hypoglycaemia as 0.5 mL/kg of 40% dextrose gel (200 mg/kg), rubbed into the buccal mucosa, followed by a feed. Compared with feeding alone, dextrose gel reduced the risk of treatment failure, intravenous treatment, and admission to the neonatal intensive care unit for treatment of hypoglycaemia, while increasing successful breastfeeding.¹⁰¹ The gel seems to have no adverse effects, including on developmental assessment at ages 4.5 and 9–10 years, and is well accepted and tolerated by infants, their families, and healthcare providers.^{65 102–104} Dextrose gel is inexpensive (a few US\$ per dose), can be made up in a hospital pharmacy, and does not require refrigeration, so it can potentially be available in many healthcare settings. The benefits might be even greater in lower income settings.¹⁰⁵ The gel is now widely recommended as a first line treatment for late preterm and term infants, although no data exist on its role, if any, in infants born at earlier gestations (table 3).^{106–109} Treatment can be repeated as needed, but most guidelines recommend an upper limit on the number of doses (usually two or three per episode of hypoglycaemia, and a maximum of five or six doses in 48 hours). This approach reflects the need for further review and possibly escalation of treatment for an infant whose hypoglycaemia is not resolving, rather than any known risk of repeated doses of gel.

Oral sucrose

In settings where resources are limited and dextrose is not readily available, sucrose has been used to prevent or treat neonatal hypoglycaemia, but high quality evidence to support its effectiveness is lacking. In principle, this approach is likely to be less immediately effective than giving dextrose. Because sucrose is a disaccharide of glucose with fructose, it requires digestion into these component sugars before uptake across the intestinal mucosa into the portal system, and therefore changes in concentrations of blood glucose can be delayed or even absent. Potentially consistent with this effect,

an Indian randomised trial (n=425) of oral sucrose solution (0.8 mL/kg of 24% solution, or 192 mg/kg), given with a feed soon after birth to infants at high risk of hypoglycaemia, did not alter blood glucose concentrations up to age six hours compared with feeding alone.¹¹⁰ In another trial in Thailand, however, 80 infants with stable hypoglycaemia born small for gestational age at 32–36 weeks' gestation were randomised to receive intravenous dextrose or expressed breast milk enriched with sucrose in similar calculated doses. No difference between the groups was seen in blood glucose concentrations six hours after treatment, or in the incidence of recurrent hypoglycaemia.¹¹¹

Intravenous dextrose

If feeding and dextrose gel do not reverse hypoglycaemia, intravenous dextrose is usually required. Recommended initial infusion rates (4–6 mg/kg/min or 60–90 mL/kg/day of 10% dextrose, table 3) are similar to neonatal glucose requirements (normally produced endogenously), with increases in volume or concentration, or both, as needed to maintain euglycaemia. Greater uncertainty exists over the use of an initial bolus as well as continuous infusion. A bolus of 1–2 mL/kg of 10% dextrose is quick and easy to administer, and achieves a prompt increase in blood glucose concentrations.¹¹² An association between high and unstable glucose concentrations after neonatal hypoglycaemia and adverse neurodevelopmental outcomes has been reported,⁵⁵ however, and infants treated with intravenous dextrose, rather than dextrose gel, formula, or breast milk, were more likely to have high and unstable glucose concentrations.⁵⁶ This finding prompted recommendations to limit the use of an initial bolus of dextrose to infants with severe or symptomatic hypoglycaemia.¹¹³ One before-and-after cohort study of 277 infants reported a graded approach to both the use of a bolus and the rate of infusion, depending on the severity of the initial hypoglycaemia. The authors reported that the graded approach improved stability of blood glucose concentrations as well as shortened the stay in the neonatal intensive care unit, and reduced costs without changing the time to achieving normoglycaemia.¹¹⁴ More trials of this and similar approaches are warranted.

Glucagon

For infants whose glucose concentrations are difficult to stabilise with intravenous dextrose, or who have repeated episodes of hypoglycaemia, other treatments should be considered. Glucagon is a peptide hormone that counteracts the effects of insulin by stimulating production of hepatic glucose. Thus glucagon is a potentially useful intervention for infants when insulin secretion is inadequately suppressed because it targets the underlying pathophysiology of the hypoglycaemia. A recent systematic

review of the use of glucagon for treatment of hypoglycaemia included seven studies (none randomised trials) with a total of 348 infants.¹¹⁵ The review reported that glucagon probably increased blood glucose concentrations by about 2.3 mmol/L after 1-2 hours, and that $\geq 80\%$ of infants treated achieved euglycaemia within four hours, but recurrent hypoglycaemia was common (55%). The certainty of evidence was very low and few data on adverse effects or long term outcomes were available. The effects did not seem to change with the dose used or the route of administration (intramuscular or intravenous bolus or infusion). Although glucagon has been given subcutaneously or intranasally in adults for emergency management of hypoglycaemia, these forms of administration have not been reported in neonates.

So far, the evidence of the role of glucagon in the management of neonatal hypoglycaemia is inadequate. Glucagon is potentially useful as a short term option, however, in circumstances where alternatives are not immediately available (eg, while arranging transfer to the neonatal intensive care unit, or when intravenous access is difficult to establish). Glucagon might also be useful to reduce the need for admission to the neonatal intensive care unit¹¹⁶ or as an adjunct treatment to reduce the intensity of secondary interventions (eg, length of intravenous infusion).

Glucocorticoids

Cortisol is a naturally occurring corticosteroid that has numerous actions on glucose metabolism, mainly by suppressing the peripheral actions of insulin and stimulating gluconeogenesis. Although secretion of cortisol is normally stimulated by physiological stress, including hypoglycaemia, neonates with hyperinsulinaemic hypoglycaemia might not generate an adequate cortisol counter-regulatory response.^{117 118} Replacement doses of cortisol are sometimes recommended if this effect is suspected.

Other treatments

Because of the uncertainty of the extent to which dextrose provides neuroprotection after hypoglycaemia and the potential for dextrose infusions to increase secretion of insulin, alternative approaches to the treatment of neonatal hypoglycaemia are being considered, including drug treatments aimed at promoting β cell adaptation. Diazoxide activates the ATP sensitive potassium channel, thereby increasing β cell membrane potential, which limits secretion of insulin. Low certainty evidence suggests that early commencement of short courses of diazoxide in at-risk infants with hypoglycaemia might promote glycaemic stability and reduce the need for intravenous dextrose,¹¹⁹ with further trial evidence awaited.⁸³

Future directions

Some of the many challenges to the research required to provide a robust evidence base for the management of neonatal hypoglycaemia include the high frequency of both risk factors and low glucose concentrations in apparently healthy infants, and the lack of reliable clinical markers of neuroglycopenia. Also, intervention studies need to be adequately powered and include long term follow-up (at least to school age) to determine clinically relevant neurodevelopmental outcomes. Some research priorities might include:

- ▶ Exploring the role of neuroprotective substrates other than glucose to stabilise neuronal metabolism without exacerbating superoxide production
- ▶ Identifying clinically applicable markers of neuroglycopenia
- ▶ Randomised trials of different thresholds for diagnosis and treatment of hypoglycaemia
- ▶ Developing new glucose monitoring techniques, including randomised trials investigating the role of glucose measurements in tissues in the screening and treatment of neonatal hypoglycaemia
- ▶ Determining which infants might benefit from screening for neonatal hypoglycaemia, including those with no commonly identified risk factors (eg, infants born large for gestational age, exposed to antenatal corticosteroids, and after caesarean section)
- ▶ Investigating effective preventive strategies for infants at risk that help reduce neonatal hypoglycaemia and improve later neurodevelopment
- ▶ Developing less invasive treatment approaches that look at the underlying pathophysiology of transitional hypoglycaemia and avoid the need for intravenous treatment and admission to the neonatal intensive care unit
- ▶ Randomised trials of different approaches to intravenous glucose treatment, including the role of an initial bolus
- ▶ Determining neurodevelopmental outcomes after asymptomatic hypoglycaemia in infants with no risk factors
- ▶ Exploring parental preferences for prevention, detection, and treatment, including perceptions of the balance of risks and benefits.

Conclusions

Neonatal hypoglycaemia is common, and could potentially be the most common cause of preventable brain injury in the newborn. For this reason, screening of infants at risk and treating low concentrations of glucose is standard practice.

In recent years, progress has been made in understanding the pathophysiology of the neonatal

metabolic transition and mechanisms of brain injury. Also, some progress in the development of a new non-invasive treatment (dextrose gel) has been made and in describing long term neurodevelopmental outcomes, particularly in infants at risk. Current approaches to detection are invasive, however, and do not meet the standard criteria for an effective screening programme. Thresholds for diagnosis are confused, and optimal treatment strategies to avoid further harm are uncertain. The effects of mild, transient hypoglycaemia and its treatment on later neurodevelopment are poorly understood. Growing evidence highlighting the potential for harm as well as benefit with all interventions, including screening and treatment, might partially explain why interpretation of the evidence has been so challenging.

More than 20 years ago, Cornblath et al noted that “The definition of clinically significant hypoglycaemia remains one of the most confused and contentious issues in contemporary neonatology.”¹²⁰ The report of a National Institutes of Health workshop published in 2009 concluded that “There has been no substantial evidence-based progress in defining what constitutes clinically significant...neonatal hypoglycaemia... Monitoring for and prevention and treatment of neonatal hypoglycaemia remain largely empirical.”¹²¹ Considerable research effort will be required to avoid these statements being just as applicable in another 20 years.

QUESTIONS FOR FUTURE RESEARCH

- ⇒ What are the optimal thresholds for diagnosis and treatment of neonatal hypoglycaemia and for which infants?
- ⇒ Who should be tested for neonatal hypoglycaemia, how should they be tested, and for how long?
- ⇒ How is hypoglycaemia best prevented and treated?
- ⇒ Does mild neonatal hypoglycaemia or its treatment, or both, influence later neurodevelopment?

PATIENT INVOLVEMENT

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

AUTHOR AFFILIATIONS

¹Liggins Institute, University of Auckland, Auckland, New Zealand

²Department of Paediatrics: Child and Youth Health, University of Auckland, Auckland, New Zealand

³Te Whatu Ora Health New Zealand, Te Toka Tumai, Auckland, New Zealand

⁴Te Whatu Ora Health New Zealand, Counties Manukau, Auckland, New Zealand

Acknowledgements We acknowledge the many colleagues who have contributed to our developing perspectives on neonatal hypoglycaemia, and particularly members of the study groups for the Children with Hypoglycaemia and Their Later Development (CHYLD) and hypoglycaemia Prevention with Oral Dextrose (hPOD) studies.

Contributors All authors contributed to the planning, writing, and editing of this review. JEH accepts responsibility for the work and the decision to publish. JEH is the guarantor.

Funding This work is funded in part by the Eunice Kennedy Shriver National Institutes of Child Health and Human Development (R01HD091075) and the Health Research Council of New Zealand (19/690). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health. The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.

Competing interests We have read and understood the BMJ policy on declaration of interests and declare the following interests: none.

Provenance and peer review Commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Jane E Harding <http://orcid.org/0000-0003-2697-1422>

REFERENCES

- 1 Harris DL, Weston PJ, Gamble GD, *et al*. Glucose profiles in healthy term infants in the first 5 days: the glucose in well babies (GLOW) study. *J Pediatr* 2020;223:34–41. [10.1016/j.jpeds.2020.02.079](https://doi.org/10.1016/j.jpeds.2020.02.079)
- 2 Anderson JM, Milner RD, Strich SJ. Effects of neonatal hypoglycaemia on the nervous system: a pathological study. *J Neurol Neurosurg Psychiatry* 1967;30:295–310. [10.1136/jnnp.30.4.295](https://doi.org/10.1136/jnnp.30.4.295)
- 3 Roeper M, Salimi Dafsari R, Hoermann H, *et al*. Risk factors for adverse neurodevelopment in transient or persistent congenital Hyperinsulinism. *Front Endocrinol (Lausanne)* 2020;11:580642. [10.3389/fendo.2020.580642](https://doi.org/10.3389/fendo.2020.580642)
- 4 Shah R, Harding J, Brown J, *et al*. Neonatal glycaemia and neurodevelopmental outcomes: a systematic review and meta-analysis. *Neonatology* 2019;115:116–26. [10.1159/000492859](https://doi.org/10.1159/000492859)
- 5 O'Brien M, Gilchrist C, Sadler L, *et al*. Infants eligible for neonatal hypoglycemia screening: a systematic review and retrospective observational cohort study. *J Pediatrics* 2023. [10.1001/jamapediatrics.2023.3957](https://doi.org/10.1001/jamapediatrics.2023.3957)
- 6 Hoermann H, Mokwa A, Roeper M, *et al*. Reliability and observer dependence of signs of neonatal hypoglycemia. *J Pediatr* 2022;245:22–9. [10.1016/j.jpeds.2022.02.045](https://doi.org/10.1016/j.jpeds.2022.02.045)
- 7 McKinlay CJD, Alswelker JM, Bailey MJ, *et al*. A better taxonomy for neonatal hypoglycemia is needed. *J Perinatol* 2021;41:1205–6. [10.1038/s41372-021-01058-x](https://doi.org/10.1038/s41372-021-01058-x)
- 8 McKinlay CJD, Alswelker JM, Anstice NS, *et al*. Association of neonatal glycaemia with neurodevelopmental outcomes at 4.5 years. *JAMA Pediatr* 2017;171:972–83. [10.1001/jamapediatrics.2017.1579](https://doi.org/10.1001/jamapediatrics.2017.1579)
- 9 Thornton PS, Stanley CA, De Leon DD, *et al*. Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. *J Pediatr* 2015;167:238–45. [10.1016/j.jpeds.2015.03.057](https://doi.org/10.1016/j.jpeds.2015.03.057)
- 10 Bailey MJ, Rout A, Harding JE, *et al*. Prolonged transitional neonatal hypoglycaemia: characterisation of a clinical syndrome. *J Perinatol* 2021;41:1149–57. [10.1038/s41372-020-00891-w](https://doi.org/10.1038/s41372-020-00891-w)
- 11 Anthony R, McKinlay CJ. Adaptation for life after birth: a review of neonatal physiology. *Anaesth Intensive Care Med* 2023;24:1–9. [10.1016/j.mpaic.2022.11.002](https://doi.org/10.1016/j.mpaic.2022.11.002)
- 12 Harris DL, Weston PJ, Harding JE. Lactate, rather than ketones, may provide alternative cerebral fuel in hypoglycaemic newborns. *Arch Dis Child Fetal Neonatal Ed* 2015;100:F161–4. [10.1136/archdischild-2014-306435](https://doi.org/10.1136/archdischild-2014-306435)
- 13 Harris DL, Weston PJ, Harding JE. Alternative cerebral fuels in the first five days in healthy term infants: the glucose in well babies (GLOW) study. *J Pediatr* 2021;231:81–6. [10.1016/j.jpeds.2020.12.063](https://doi.org/10.1016/j.jpeds.2020.12.063)

- 14 Futatani T, Ina S, Shima A, *et al.* Exclusive breast-feeding and postnatal changes in blood sodium, ketone, and glucose levels. *Pediatr Int* 2019;61:471–4. 10.1111/ped.13824
- 15 Susa JB, McCormick KL, Widness JA, *et al.* Chronic hyperinsulinemia in the fetal rhesus monkey: effects on fetal growth and composition. *Diabetes* 1979;28:1058–63. 10.2337/diab.28.12.1058
- 16 Girard JR, Kervran A, Soufflet E, *et al.* Factors affecting the secretion of insulin and glucagon by the rat fetus. *Diabetes* 1974;23:310–7. 10.2337/diab.23.4.310
- 17 Marconi AM, Paolini C, Buscaglia M, *et al.* The impact of gestational age and fetal growth on the maternal-fetal glucose concentration difference. *Obstet Gynecol* 1996;87:937–42. 10.1016/0029-7844(96)00048-8
- 18 Nicolini U, Hubinont C, Santolaya J, *et al.* Maternal-fetal glucose gradient in normal pregnancies and in pregnancies complicated by alloimmunization and fetal growth retardation. *Am J Obstet Gynecol* 1989;161:924–7. 10.1016/0002-9378(89)90753-9
- 19 Wang J, Shen S, Price MJ, *et al.* Glucose, insulin, and lipids in cord blood of neonates and their association with birthweight: differential metabolic risk of large for gestational age and small for gestational age babies. *J Pediatr* 2020;220:64–72. 10.1016/j.jpeds.2020.01.013
- 20 Vanspranghels R, Houfflin-Debarge V, Deken V, *et al.* Umbilical cord arterial and venous gases, ionogram, and glucose level for predicting neonatal morbidity at term. *Eur J Obstet Gynecol Reprod Biol* 2020;252:181–6. 10.1016/j.ejogrb.2020.06.022
- 21 Zanardo V, Mari G, de Luca F, *et al.* Lactate in cord blood and its relation to fetal gluconeogenesis in at term deliveries. *Early Hum Dev* 2015;91:165–8. 10.1016/j.earhumdev.2015.01.003
- 22 Smolkin T, Ulanovsky I, Carasso P, *et al.* Standards of admission capillary blood glucose levels in cesarean born neonates. *World J Pediatr* 2017;13:433–8. 10.1007/s12519-017-0016-7
- 23 Matterberger C, Baik-Schneditz N, Schwaberg B, *et al.* Blood glucose and cerebral tissue oxygenation immediately after birth-an observational study. *J Pediatr* 2018;200:19–23. 10.1016/j.jpeds.2018.05.008
- 24 Alkalay AL, Sarnat HB, Flores-Sarnat L, *et al.* Population meta-analysis of low plasma glucose thresholds in full-term normal newborns. *Am J Perinatol* 2006;23:115–9. 10.1055/s-2006-931912
- 25 Levy-Khademi F, Perry A, Klinger G, *et al.* Normal point of care glucose values after birth in the well-baby nursery. *Am J Perinatol* 2019;36:219–24. 10.1055/s-0038-1667293
- 26 Mukunya D, Odongkara B, Piloya T, *et al.* Prevalence and factors associated with neonatal hypoglycemia in northern Uganda: a community-based cross-sectional study. *Trop Med Health* 2020;48:89. 10.1186/s41182-020-00275-y
- 27 McKinlay CJD, Dalziel SR, Harding JE. Antenatal glucocorticoids: where are we after forty years? *J Dev Orig Health Dis* 2015;6:127–42. 10.1017/S2040174414000579
- 28 Kalhan S, Parimi P. Gluconeogenesis in the fetus and neonate. *Semin Perinatol* 2000;24:94–106. 10.1053/sp.2000.6360
- 29 Sperling MA, Ganguli S, Leslie N, *et al.* Fetal-perinatal catecholamine secretion: role in perinatal glucose homeostasis. *Am J Physiol* 1984;247(1 Pt 1):E69–74. 10.1152/ajpendo.1984.247.1.E69
- 30 Mehta A, Wootton R, Cheng KN, *et al.* Effect of diazoxide or glucagon on hepatic glucose production rate during extreme neonatal hypoglycaemia. *Arch Dis Child* 1987;62:924–30. 10.1136/ad.62.9.924
- 31 Ktorza A, Bihoreau MT, Nurjhan N, *et al.* Insulin and glucagon during the perinatal period: secretion and metabolic effects on the liver. *Biol Neonate* 1985;48:204–20. 10.1159/000242173
- 32 Helman A, Cangelosi AL, Davis JC, *et al.* A nutrient-sensing transition at birth triggers glucose-responsive insulin secretion. *Cell Metab* 2020;31:1004–16. 10.1016/j.cmet.2020.04.004
- 33 Sunehag A, Gustafsson J, Ewald U. Glycerol carbon contributes to hepatic glucose production during the first eight hours in healthy term infants. *Acta Paediatr* 1996;85:1339–43. 10.1111/j.1651-2227.1996.tb13921.x
- 34 Sunehag AL. The role of parenteral lipids in supporting gluconeogenesis in very premature infants. *Pediatr Res* 2003;54:480–6. 10.1203/01.PDR.000081298.06751.76
- 35 Vizek K, Rázová M, Melichar V. Lipolytic effect of TSH, glucagon and hydrocortisone on the adipose tissue of newborns and adults in vitro. *Physiol Bohemoslov* 1979;28:325–31.
- 36 Marcus C, Ehrén H, Bolme P, *et al.* Regulation of lipolysis during the neonatal period. Importance of thyrotropin. *J Clin Invest* 1988;82:1793–7. 10.1172/JCI113793
- 37 Girard J. Metabolic adaptations to change of nutrition at birth. *Biol Neonate* 1990;58(Suppl 1):3–15. 10.1159/000243294
- 38 Limesand SW, Rozance PJ. Fetal adaptations in insulin secretion result from high catecholamines during placental insufficiency. *J Physiol* 2017;595:5103–13. 10.1113/JP273324
- 39 Yang J, Hammoud B, Li C, *et al.* Decreased KATP channel activity contributes to the low glucose threshold for insulin secretion of rat neonatal islets. *Endocrinology* 2021;162:bqab121. 10.1210/endo/bqab121
- 40 Quesada-Candela C, Tudurí E, Marroquí L, *et al.* Morphological and functional adaptations of pancreatic alpha-cells during late pregnancy in the mouse. *Metabolism* 2020;102:153963. 10.1016/j.metabol.2019.153963
- 41 Avagliano L, Mascherpa M, Massa V, *et al.* Fetal pancreatic langerhans islets size in pregnancies with metabolic disorders. *J Matern Fetal Neonatal Med* 2019;32:3589–94. 10.1080/14767058.2018.1468878
- 42 Szlapinski SK, Bennett J, Strutt BJ, *et al.* Increased alpha and beta cell mass during mouse pregnancy is not dependent on transdifferentiation. *Exp Biol Med (Maywood)* 2021;246:617–28. 10.1177/1535370220972686
- 43 Flisher MF, Shin D, Huising MO. Urocortin3: local inducer of somatostatin release and bellwether of beta cell maturity. *Peptides* 2022;151. 10.1016/j.peptides.2022.170748
- 44 Hertel J, Kühl C. Metabolic adaptations during the neonatal period in infants of diabetic mothers. *Acta Endocrinol* 1986;113(3_Suppl):S136–40. 10.1530/acta.0.11150136
- 45 Ahlsson FSE, Diderholm B, Ewald U, *et al.* Lipolysis and insulin sensitivity at birth in infants who are large for gestational age. *Pediatrics* 2007;120:958–65. 10.1542/peds.2007-0165
- 46 Cowett RM, Rapoza RE, Gelardi NL. Insulin counterregulatory hormones are ineffective in neonatal hyperinsulinemic hypoglycemia. *Metabolism* 1999;48:568–74. 10.1016/s0026-0495(99)90052-5
- 47 Vannucci RC, Vannucci SJ. Glucose metabolism in the developing brain. *Semin Perinatol* 2000;24:107–15. 10.1053/sp.2000.6361
- 48 De Angelis LC, Brigati G, Polleri G, *et al.* Neonatal hypoglycemia and brain vulnerability. *Front Endocrinol (Lausanne)* 2021;12:634305. 10.3389/fendo.2021.634305
- 49 Suh SW, Hamby AM, Swanson RA. Hypoglycemia, brain energetics, and hypoglycemic neuronal death. *Glia* 2007;55:1280–6. 10.1002/glia.20440
- 50 Lyons SA, Kettenmann H. Oligodendrocytes and microglia are selectively vulnerable to combined hypoxia and hypoglycemia injury in vitro. *J Cereb Blood Flow Metab* 1998;18:521–30. 10.1097/00004647-199805000-00007
- 51 Yan H, Rivkees SA. Hypoglycemia influences oligodendrocyte development and myelin formation. *Neuroreport* 2006;17:55–9. 10.1097/01.wnr.0000192733.00535.b6
- 52 Suh SW, Gum ET, Hamby AM, *et al.* Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase. *J Clin Invest* 2007;117:910–8. 10.1172/JCI30077
- 53 Kaiser JR, Bai S, Gibson N, *et al.* Association between transient newborn hypoglycemia and fourth-grade achievement test proficiency: a population-based study. *JAMA Pediatr* 2015;169:913. 10.1001/jamapediatrics.2015.1631
- 54 Shah R, Dai DWT, Alswelner JM, *et al.* Association of neonatal hypoglycemia with academic performance in mid-childhood. *JAMA* 2022;327:1158–70. 10.1001/jama.2022.0992
- 55 McKinlay CJD, Alswelner JM, Ansell JM, *et al.* Neonatal hypoglycemia and neurodevelopmental outcomes at 2 years. *N Engl J Med* 2015;373:1507–18. 10.1056/NEJMoa1504909
- 56 Burakevych N, McKinlay CJD, Harris DL, *et al.* Factors influencing glycaemic stability after neonatal hypoglycaemia and relationship to neurodevelopmental outcome. *Sci Rep* 2019;9:8132. 10.1038/s41598-019-44609-1
- 57 Yamada KA, Rensing N, Thio LL. Ketogenic diet reduces hypoglycemia-induced neuronal death in young rats. *Neurosci Lett* 2005;385:210–4. 10.1016/j.neulet.2005.05.038
- 58 Suh SW, Aoyama K, Matsumori Y, *et al.* Pyruvate administered after severe hypoglycemia reduces neuronal death and cognitive impairment. *Diabetes* 2005;54:1452–8. 10.2337/diabetes.54.5.1452
- 59 Won SJ, Jang BG, Yoo BH, *et al.* Prevention of acute/severe hypoglycemia-induced neuron death by lactate administration. *J Cereb Blood Flow Metab* 2012;32:1086–96. 10.1038/jcbfm.2012.30
- 60 Alswelner JM, Heather N, Harris DL, *et al.* Application of the screening test principles to screening for neonatal hypoglycemia. *Front Pediatr* 2022;10:1048897. 10.3389/fped.2022.1048897
- 61 Wilson JMG, Jungner G. Principles and practice of screening for disease. *WHO Chron* 1968;22:281–393.
- 62 UK National Screening Committee. *Criteria for a targeted screening programme*. Gov.UK. 2022. Available: <https://www.gov.uk/government/publications/evidence-review-criteria-national-screening-programmes/criteria-for-a-targeted-screening-programme>
- 63 Andermann A, Blancaquaert I, Beauchamp S, *et al.* Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. *Bull World Health Organ* 2008;86:317–9. 10.2471/blt.07.050112
- 64 Horwitz J, Mardiros L, Musa A, *et al.* Scoping review of evidence for managing postnatal hypoglycaemia. *BMJ Open* 2022;12:e053047. 10.1136/bmjopen-2021-053047

- 65 Edwards T, Liu G, Battin M, *et al.* Oral dextrose GEL for the treatment of hypoglycaemia in newborn infants. *Cochrane Database Syst Rev* 2022;3:CD011027. 10.1002/14651858.CD011027.pub3
- 66 Napiórkowska-Orkisz M, Gutysz-Wojnicka A, Tanajewska M, *et al.* Evaluation of methods to minimize pain in newborns during capillary blood sampling for screening: a randomized clinical trial. *Int J Environ Res Public Health* 2022;19:870. 10.3390/ijerph19020870
- 67 Mukhopadhyay S, Wade KC, Dhudasia MB, *et al.* Clinical impact of neonatal hypoglycemia screening in the well-baby care. *J Perinatol* 2020;40:1331–8. 10.1038/s41372-020-0641-1
- 68 Saginur M, Abdounour J, Guérin E, *et al.* Association between newborn hypoglycemia screening and breastfeeding success in an Ottawa, Ontario, hospital: a retrospective cohort study. *CMAJ Open* 2023;11:E381–8. 10.9778/cmajo.20210324
- 69 Longmore DK, Barr ELM, Wilson AN, *et al.* Associations of gestational diabetes and type 2 diabetes during pregnancy with breastfeeding at hospital discharge and up to 6 months: the PANDORA study. *Diabetologia* 2020;63:2571–81. 10.1007/s00125-020-05271-9
- 70 Identification and management of neonatal hypoglycaemia in the full term infant: framework for practice. 2017 British Association of Perinatal Medicine. 2017. Available: https://hubble-live-assets.s3.amazonaws.com/bapm/file_asset/file/37/Identification_and_Management_of_Neonatal_Hypoglycaemia_in_the_full_term_infant_-_A_Framework_for_Practice_revised_Oct_2017.pdf
- 71 van Kempen AAMW, Eskes PF, Nuytemans DHGM, *et al.* Lower versus traditional treatment threshold for neonatal hypoglycemia. *N Engl J Med* 2020;382:534–44. 10.1056/NEJMoa1905593
- 72 Harris DL, Weston PJ, Battin MR, *et al.* A survey of the management of neonatal hypoglycaemia within the Australian and New Zealand neonatal network. *J Paediatr Child Health* 2014;50:E55–62. 10.1111/j.1440-1754.2009.01599.x
- 73 Glasgow MJ, Harding JE, Edlin R, *et al.* Cost analysis of cot-side screening methods for neonatal hypoglycaemia. *Neonatology* 2018;114:155–62. 10.1159/000489080
- 74 Harris DL, Weston PJ, Harding JE. Incidence of neonatal hypoglycemia in babies identified as at risk. *J Pediatr* 2012;161:787–91. 10.1016/j.jpeds.2012.05.022
- 75 Cummings CT, Ritter V, LeBlanc S, *et al.* Evaluation of risk factors and approach to screening for asymptomatic neonatal hypoglycemia. *Neonatology* 2022;119:77–83. 10.1159/000520512
- 76 Chen Y-S, Ho C-H, Lin S-J, *et al.* Identifying additional risk factors for early asymptomatic neonatal hypoglycemia in term and late preterm babies. *Pediatr Neonatol* 2022;63:625–32. 10.1016/j.pedneo.2022.04.011
- 77 Edwards T, Alswailer JM, Gamble GD, *et al.* Neurocognitive outcomes at age 2 years after neonatal hypoglycemia in a cohort of participants from the hPOD randomized trial. *JAMA Netw Open* 2022;5:e2235989. 10.1001/jamanetworkopen.2022.35989
- 78 Adamkin DH. Committee on fetus and newborn. Postnatal glucose homeostasis in late-preterm and term infants. *Pediatrics* 2011;127:575–9. 10.1542/peds.2010-3851
- 79 McKinlay CJD, Chase JG, Dickson J, *et al.* Continuous glucose monitoring in neonates: a review. *Matern Health Neonatol Perinatol* 2017;3:18. 10.1186/s40748-017-0055-z
- 80 Harris DL, Battin MR, Williams CE, *et al.* Cot-side electro-encephalography and interstitial glucose monitoring during insulin-induced hypoglycaemia in newborn lambs. *Neonatology* 2009;95:271–8. 10.1159/000166847
- 81 Harris DL, Battin MR, Weston PJ, *et al.* Continuous glucose monitoring in newborn babies at risk of hypoglycemia. *J Pediatr* 2010;157:198–202. 10.1016/j.jpeds.2010.02.003
- 82 Tiberi E, Cota F, Barone G, *et al.* Continuous glucose monitoring in Preterm infants: evaluation by a modified Clarke error grid. *Ital J Pediatr* 2016;42:29. 10.1186/s13052-016-0236-9
- 83 Laing D, Walsh E, Alswailer JM, *et al.* Oral diazoxide versus placebo for severe or recurrent neonatal hypoglycaemia: neonatal glucose care optimisation (neogluco) study - a randomised controlled trial. *BMJ Open* 2022;12:e059452. 10.1136/bmjopen-2021-059452
- 84 Signal M, Le Compte A, Harris DL, *et al.* Impact of retrospective calibration algorithms on hypoglycemia detection in newborn infants using continuous glucose monitoring. *Diabetes Technol Ther* 2012;14:883–90. 10.1089/dia.2012.0111
- 85 Dixon J, Campbell JD, Holder-Pearson LR, *et al.* Open-Access, Light-Based, Wearable Glucose Sensor: Towards a Low-Cost Equitable Artificial Pancreas System. Scotland: IEEE Engineering Medicine Biology Society, 2022.
- 86 Montassir H, Maegaki Y, Ogura K, *et al.* Associated factors in neonatal hypoglycemic brain injury. *Brain Dev* 2009;31:649–56. 10.1016/j.braindev.2008.10.012
- 87 Wickström R, Skiöld B, Petersson G, *et al.* Moderate neonatal hypoglycemia and adverse neurological development at 2-6 years of age. *Eur J Epidemiol* 2018;33:1011–20. 10.1007/s10654-018-0425-5
- 88 Hegarty JE, Harding JE, Gamble GD, *et al.* Prophylactic oral dextrose GEL for newborn babies at risk of neonatal hypoglycaemia: a randomised controlled dose-finding trial (the pre-hPOD study). *PLoS Med* 2016;13:e1002155. 10.1371/journal.pmed.1002155
- 89 Harding JE, Hegarty JE, Crowther CA, *et al.* Evaluation of oral dextrose GEL for prevention of neonatal hypoglycemia (hPOD): a multicenter, double-blind randomized controlled trial. *PLoS Med* 2021;18:e1003411. 10.1371/journal.pmed.1003411
- 90 Griffith R, Hegarty JE, Alswailer JM, *et al.* Two-year outcomes after dextrose GEL prophylaxis for neonatal hypoglycaemia. *Arch Dis Child Fetal Neonatal Ed* 2021;106:278–85. 10.1136/archdischild-2020-320305
- 91 Edwards T, Alswailer JM, Crowther CA, *et al.* Prophylactic oral dextrose GEL and neurosensory impairment at 2-year follow-up of participants in the hPOD randomized trial. *JAMA* 2022;327:1149–57. 10.1001/jama.2022.2363
- 92 Boluyt N, van Kempen A, Offringa M. Neurodevelopment after neonatal hypoglycemia: a systematic review and design of an optimal future study. *Pediatrics* 2006;117:2231–43. 10.1542/peds.2005-1919
- 93 Harris DL, Gamble GD, Weston PJ, *et al.* What happens to blood glucose concentrations after oral treatment for neonatal hypoglycemia. *J Pediatr* 2017;190:136–41. 10.1016/j.jpeds.2017.06.034
- 94 Flaherman VJ, Gay B, Scott C, *et al.* Randomised trial comparing hand expression with breast pumping for mothers of term newborns feeding poorly. *Arch Dis Child Fetal Neonatal Ed* 2012;97:F18–23. 10.1136/adc.2010.209213
- 95 Saint L, Smith M, Hartmann PE. The yield and nutrient content of colostrum and milk of women from giving birth to 1 month postpartum. *Br J Nutr* 1984;52:87–95. 10.1079/bjn19840074
- 96 Harris DL, Weston PJ, Harding JE. Relationships between feeding and glucose concentrations in healthy term infants during the first five days after birth—the glucose in well babies study (GLOW). *Front Pediatr* 2023;11. 10.3389/fped.2023.1147659
- 97 Uvnäs-moberg K, Widström AM, Marchini G, *et al.* Release of GI hormones in mother and infant by sensory stimulation. *Acta Paediatrica* 1987;76:851–60. 10.1111/j.1651-2227.1987.tb17254.x
- 98 Sen S, Andrews C, Anderson E, *et al.* Type of feeding provided with dextrose GEL impacts hypoglycemia outcomes: comparing donor milk, formula, and breastfeeding. *J Perinatol* 2020;40:1705–11. 10.1038/s41372-020-00776-y
- 99 Forster DA, Moorhead AM, Jacobs SE, *et al.* Advising women with diabetes in pregnancy to express breastmilk in late pregnancy (diabetes and antenatal milk expressing [DAME]): a multicentre, unblinded, randomised controlled trial. *Lancet* 2017;389:2204–13. 10.1016/S0140-6736(17)31373-9
- 100 Oladimeji OL, Harding JE, Crowther CA, *et al.* Expressed breast milk and maternal expression of breast milk for the prevention and treatment of neonatal hypoglycemia – a systematic review and meta-analysis. *Matern Health Neonatol Perinatol* 2023;9. 10.1186/s40748-023-00166-0
- 101 Harris DL, Weston PJ, Signal M, *et al.* Dextrose GEL for neonatal hypoglycaemia (the sugar babies study): a randomised, double-blind, placebo-controlled trial. *Lancet* 2013;382:2077–83. 10.1016/S0140-6736(13)61645-1
- 102 St Clair SL, Dai DWT, Harris DL, *et al.* Mid-childhood outcomes after dextrose GEL treatment of neonatal hypoglycaemia: follow-up of the sugar babies randomized trial. *Neonatology* 2023;120:90–101. 10.1159/000527715
- 103 Harris DL, Alswailer JM, Ansell JM, *et al.* Outcome at 2 years after dextrose GEL treatment for neonatal hypoglycemia: follow-up of a randomized trial. *J Pediatr* 2016;170:54–9. 10.1016/j.jpeds.2015.10.066
- 104 Harris DL, Gamble GD, Harding JE, *et al.* Outcome at 4.5 years after dextrose GEL treatment of hypoglycaemia: follow-up of the sugar babies randomised trial. *Arch Dis Child Fetal Neonatal Ed* 2023;108:121–8. 10.1136/archdischild-2022-324148
- 105 Gupta K, Amboiram P, Balakrishnan U, *et al.* Dextrose GEL for neonates at risk with asymptomatic hypoglycemia: a randomized clinical trial. *Pediatrics* 2022;149. 10.1542/peds.2021-050733
- 106 Levene I, Wilkinson D. Identification and management of neonatal hypoglycaemia in the full-term infant (British Association of Perinatal Medicine-framework for practice). *Arch Dis Child Educ Pract Ed* 2019;104:29–32. 10.1136/archdischild-2017-314050
- 107 Narvey MR, Marks SD. The screening and management of newborns at risk for low blood glucose. *Paediatr Child Health* 2019;24:536–54. 10.1093/pch/pxz134
- 108 Wackernagel D, Gustafsson A, Edstedt Bonamy A-K, *et al.* Swedish national guideline for prevention and treatment of neonatal hypoglycaemia in newborn infants with gestational age >=35 weeks. *Acta Paediatrica* 2020;109:31–44. 10.1111/apa.14955
- 109 Wight NE, Breastfeeding M. ABM clinical protocol #1: guidelines for glucose monitoring and treatment of hypoglycemia in term and late preterm neonates, revised 2021. *Breastfeed Med* 2021;16:353–65. 10.1089/bfm.2021.29178.new

- 110 Surachaidungtavil S, Chanvorachote P, Suksumek N. A randomized control trial of oral sucrose solution for prevention of hypoglycemia in high risk infants. *In Vivo* 2020;34:1493–7. 10.21873/invivo.11935
- 111 Bora R, Deori S. Transitional hypoglycaemia management in small for gestational age neonates with sucrose enriched expressed breastmilk in resource poor setting. *J Trop Pediatr* 2020;66:267–74. 10.1093/tropej/fmzo64
- 112 Lilien LD, Pildes RS, Srinivasan G, *et al.* Treatment of neonatal hypoglycemia with minibolus and intravenous glucose infusion. *J Pediatr* 1980;97:295–8. 10.1016/s0022-3476(80)80499-9
- 113 Rozance PJ, Hay WW. New approaches to management of neonatal hypoglycemia. *Matern Health Neonatol Perinatol* 2016;2:3. 10.1186/s40748-016-0031-z
- 114 Sen S, Cherkerzian S, Turner D, *et al.* A graded approach to intravenous dextrose for neonatal hypoglycemia decreases blood glucose variability, time in the neonatal intensive care unit, and cost of stay. *J Pediatr* 2021;231:74–80. 10.1016/j.jpeds.2020.12.025
- 115 Walsh EPG, Alsweller JM, Ardern J, *et al.* Glucagon for neonatal hypoglycaemia: systematic review and meta-analysis. *Neonatology* 2022;119:285–94. 10.1159/000522415
- 116 Kasirer Y, Dotan O, Mimouni FB, *et al.* The use of intramuscular glucagon to prevent IV glucose infusion in early neonatal hypoglycemia. *J Perinatol* 2021;41:1158–65. 10.1038/s41372-021-00925-x
- 117 Ahmed S, Soliman A, De Sanctis V, *et al.* Defective cortisol secretion in response to spontaneous hypoglycemia but normal cortisol response to ACTH stimulation in neonates with hyperinsulinemic hypoglycemia (HH). *Acta Biomed* 2021;92:e2021182. 10.23750/abm.v92i2.11396
- 118 Hussain K, Hindmarsh P, Aynsley-Green A. Neonates with symptomatic hyperinsulinemic hypoglycemia generate inappropriately low serum cortisol counterregulatory hormonal responses. *J Clin Endocrinol Metab* 2003;88:4342–7. 10.1210/jc.2003-030135
- 119 Laing D, Hanning SM, Harding JE, *et al.* Diazoxide for the treatment of transitional neonatal hypoglycemia: a systematic review. *J Neonatol* 2021;35:203–8. 10.1177/09732179211059607
- 120 Cornblath M, Hawdon JM, Williams AF, *et al.* Controversies regarding definition of neonatal hypoglycemia: suggested operational thresholds. *Pediatrics* 2000;105:1141–5. 10.1542/peds.105.5.1141
- 121 Hay WW, Raju TN, Higgins RD, *et al.* Knowledge gaps and research needs for understanding and treating neonatal hypoglycemia: workshop report from Eunice Kennedy Shriver National Institute of Child Health and Human Development. *J Pediatr* 2009;155:612–7. 10.1016/j.jpeds.2009.06.044
- 122 Williams AF. Hypoglycaemia of the newborn: a review. *Bull World Health Organ* 1997;75:261–90.
- 123 S Das-Kundu Z, J Fontijn Z, M Mönkhoff Z, *et al.* Prevention and treatment of hypoglycaemia in neonates with a gestational age from 35 o/7 weeks in maternity wards. 2023. Available: <https://www.neonet.ch/>
- 124 Queensland clinical guidelines: hypoglycaemia - newborn: Queensland Government Department of health. 2022. Available: www.health.qld.gov.au/qcgc